The Quantellect read.As of Nov 19, 2026, 13 active firms cover Mirum Pharmaceuticals Inc: 13 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $118.00 to $200.00, a moderate spread. The average target of $149.00 sits 61% above the current $92.51. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.67 next quarter toward $0.32 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 active firms
Buy
Strong Buy00%
Buy13100%
Neutral00%
Sell00%
Strong Sell00%
Based on 13 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$149.00
+61.1% upside
Average target across 12 active firms as of Nov 19, 2026 vs $92.51 current
Highest Target$200.00
Average Target$149.00
Lowest Target$118.00
Detailed analyst forecasts for MIRM
Showing 1–14 of 14 named analysts shown · 13 active firms in the rating projection
As of Nov 19, 2026, 13 of 13 active firms rate MIRM a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MIRM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.67
Range $-0.97 – $-0.43 · 7 analysts · -95% YoY
Next period, 7 analysts expect Mirum Pharmaceuticals Inc to earn $-0.67 a share (range $-0.97 – $-0.43), versus $-13.43 a year earlier. Full-year consensus is $-15.67, growing to $0.32 the year after.
REVENUE · NEXT QUARTER
$198.7M
Range $188.4M – $210.6M · 7 analysts · +24% YoY
Revenue is expected to reach $198.7M (range $188.4M – $210.6M), +24.3% year-over-year. Full-year consensus is $717.6M, rising to $868.6M next year.
Top analysts covering Mirum Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MIRM.
#1
Jonathan Wolleben
JMP Securities · Rank #54
Buy
$167.00+80.5% to target
Overall win rate
43%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #100
Buy
No targeton MIRM
Overall win rate
54%
+ Follow
#3
Josh Schimmer
Cantor Fitzgerald · Rank #132
Buy
$95.00+2.7% to target
Overall win rate
44%
+ Follow
#4
Joseph Schwartz
Leerink Partners · Rank #242
Buy
$154.00+66.5% to target
Overall win rate
36%
+ Follow
#5
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$202.00+118.4% to target
Overall win rate
38%
+ Follow
MIRM stock forecast FAQ
What is MIRM's average 12-month price target?+
The 12 active firms with a live target average $149.00 for Mirum Pharmaceuticals Inc over the next 12 months, ranging from a $200.00 high to a $118.00 low, as of Nov 19, 2026.
Is MIRM stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 13 active firms as of Nov 19, 2026, 13 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MIRM?+
The Street-high target is $200.00 (HC Wainwright & Co.), and the Street-low is $118.00 (Leerink Partners). The average of all 12 active-firm targets is $149.00.
How many active Wall Street firms cover MIRM?+
13 active firms have a recognized rating on Mirum Pharmaceuticals Inc as of Nov 19, 2026, and 12 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MIRM?+
Among analysts who currently cover MIRM, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #54). Their current call is Buy with a $167.00 target.
What is Mirum Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.67 per share (range $-0.97 – $-0.43) across 7 analysts. Full-year EPS is projected at $-15.67, rising to $0.32 the following year.
How much revenue is Mirum Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $198.7M (range $188.4M – $210.6M). Full-year revenue is projected at $717.6M, growing to $868.6M next year.
Have analysts been upgrading or downgrading MIRM lately?+
As of Nov 19, 2026, 13 of 13 active firms rate MIRM a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MIRM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.